UBS Group
STRO icon

UBS Group’s Sutro Biopharma STRO Stock Holding History

UBS Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.79M Buy
392,871
+385,001
+4,892% +$6.96M ﹤0.01% 3375
2025
Q4 		$91.1K Sell
7,870
-176,714
-96% -$1.68M ﹤0.01% 6954
2025
Q3 		$1.6M Buy
184,584
+22,696
+14% +$193K ﹤0.01% 5170
2025
Q2 		$1.16M Buy
161,888
+154,331
+2,042% +$1.26M ﹤0.01% 5320
2025
Q1 		$49.2K Sell
7,557
-10,809
-59% -$170K ﹤0.01% 7607
2024
Q4 		$338K Buy
18,366
+1,780
+11% +$54.3K ﹤0.01% 6115
2024
Q3 		$574K Buy
16,586
+13,451
+429% +$527K ﹤0.01% 5119
2024
Q2 		$91.9K Sell
3,135
-3,329
-52% -$132K ﹤0.01% 6232
2024
Q1 		$365K Buy
6,464
+505
+8% +$22.3K ﹤0.01% 5433
2023
Q4 		$256K Buy
5,959
+2,362
+66% +$75K ﹤0.01% 5616
2023
Q3 		$125K Buy
3,597
+591
+20% +$25.7K ﹤0.01% 5685
2023
Q2 		$140K Sell
3,006
-5,264
-64% -$262K ﹤0.01% 5744
2023
Q1 		$382K Buy
8,270
+1,004
+14% +$63.7K ﹤0.01% 4901
2022
Q4 		$587K Buy
7,266
+7,158
+6,628% +$497K ﹤0.01% 4566
2022
Q3 		$6K Sell
108
-264
-71% -$15.6K ﹤0.01% 9065
2022
Q2 		$19K Sell
372
-10,661
-97% -$596K ﹤0.01% 6952
2022
Q1 		$907K Buy
+11,033
New +$1.05M ﹤0.01% 4205
2021
Q4 		– Sell
-122
Closed -$23K – 10685
2021
Q3 		$23K Buy
+122
New +$23.2K ﹤0.01% 7023
2021
Q2 		– Sell
-51
Closed -$12K – 9801
2021
Q1 		$12K Buy
+51
New +$12.1K ﹤0.01% 7808
2020
Q4 		– Sell
-75
Closed -$8K – 8737
2020
Q3 		$8K Sell
75
-463
-86% -$43.7K ﹤0.01% 7045
2020
Q2 		$42K Sell
538
-125
-19% -$12K ﹤0.01% 6013
2020
Q1 		$68K Sell
663
-683
-51% -$71.8K ﹤0.01% 5584
2019
Q4 		$148K Buy
1,346
+477
+55% +$49.2K ﹤0.01% 5790
2019
Q3 		$79K Buy
869
+672
+341% +$67.9K ﹤0.01% 5910
2019
Q2 		$22K Buy
+197
New +$21.7K ﹤0.01% 6551
2019
Q1 		– Sell
-376
Closed -$34K – 8145
2018
Q4 		$34K Buy
376
+251
+201% +$30.3K ﹤0.01% 6389
2018
Q3 		$19K Buy
+125
New +$18.9K ﹤0.01% 6828

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

UBS Group's STRO Position: Q1 2026 in Review

UBS Group increased its Sutro Biopharma (STRO) stake by 4,892% in Q1 2026, buying an estimated $6.96M and bringing the position to 392,871 shares worth $9.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3375.

UBS Group first reported a position in STRO in Q3 2018 and has held it in 27 quarters since. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • UBS Group held 392,871 shares of Sutro Biopharma worth $9.79M as of Q1 2026.
  • UBS Group bought 385,001 Sutro Biopharma shares in Q1 2026, an estimated $6.96M.
  • Sutro Biopharma made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3375 holding.
  • UBS Group first reported a position in Sutro Biopharma in Q3 2018 and has held it in 27 quarters since.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.